# Strict IGF-1 Control in Acromegaly

> **NCT02952885** · PHASE3 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 10 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Pegvisomant

## Key facts

- **NCT ID:** NCT02952885
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-27
- **Primary completion:** 2020-05-07
- **Final completion:** 2020-05-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952885, "Strict IGF-1 Control in Acromegaly". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02952885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*